Electra Therapeutics
South San Francisco, United States · Biotechnology, Health Care, Manufacturing · 36 employees
Electra Therapeutics is a clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer.
Funding history
- Venture - Series Unknown · $850.0M · Jul 2026
- Funding Round · $30.0M · Mar 2026
- Series C · $183.0M · Oct 2025
- Venture - Series Unknown · $180.4M · Jan 2025
- Series B · $84.0M · Feb 2022
Recent signals
- Jul 21, 2026: Raised $850.0M in Venture - Series Unknown
- Mar 11, 2026: Raised $30.0M in Funding Round
- Oct 22, 2025: Raised $183.0M in Series C
- Apr 25, 2025: Electra secures $186M Series B funding round co-led by Capricorn Investment Group and Temasek
- Jan 02, 2025: Raised $180.4M in Venture - Series Unknown
- Dec 17, 2024: Electra and Interfer Sign MOU to Collaborate on Clean Iron and Green Steel Production
- Nov 04, 2024: Launched Electra Therapeutics, Inc. announces FDA Fast Track designation for ELA026 to treat secondary hemophagocytic lymphohistiocytosis.
- Aug 29, 2024: Electrasteel Inc. Appoints James Rutland as Chief Financial Officer and Steve MacManus as Vice President of Engineering
See plans & pricing → Track Electra Therapeutics’s funding, hiring and signals, with verified contacts, on Fundz.
Fundz watches Electra Therapeutics across 18 signal types, from funding and M&A to exec moves and hiring.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.